PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
1.65%
Revenue growth under 50% of AVGO's 5.03%. Michael Burry would suspect a deteriorating sales pipeline or weaker brand.
5.39%
Gross profit growth at 75-90% of AVGO's 6.12%. Bill Ackman would demand operational improvements to match competitor gains.
44.97%
EBIT growth above 1.5x AVGO's 8.76%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
40.47%
Operating income growth above 1.5x AVGO's 8.76%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
75.78%
Net income growth above 1.5x AVGO's 8.21%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
78.95%
EPS growth above 1.5x AVGO's 7.27%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
76.32%
Diluted EPS growth above 1.5x AVGO's 7.41%. David Dodd would see if there's a robust moat protecting these shareholder gains.
-0.88%
Share reduction while AVGO is at 0.41%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-1.13%
Reduced diluted shares while AVGO is at 0.00%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
0.37%
Dividend growth under 50% of AVGO's 15.15%. Michael Burry might suspect more pressing needs for cash or weaker earnings power.
78.07%
Positive OCF growth while AVGO is negative. John Neff would see this as a clear operational advantage vs. the competitor.
98.87%
Positive FCF growth while AVGO is negative. John Neff would see a strong competitive edge in net cash generation.
128.08%
10Y revenue/share CAGR above 1.5x AVGO's 20.57%. David Dodd would confirm if management’s strategic vision consistently outperforms the competitor.
16.05%
5Y revenue/share CAGR at 75-90% of AVGO's 20.57%. Bill Ackman would encourage strategies to match competitor’s pace.
30.73%
3Y revenue/share CAGR at 50-75% of AVGO's 45.14%. Martin Whitman would question if the firm lags behind competitor innovations.
221.77%
10Y OCF/share CAGR above 1.5x AVGO's 86.34%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
-1.55%
Negative 5Y OCF/share CAGR while AVGO is at 86.34%. Joel Greenblatt would question the firm’s operational model or cost structure.
60.07%
3Y OCF/share CAGR under 50% of AVGO's 258.97%. Michael Burry would worry about a significant short-term disadvantage in generating operational cash.
530.73%
Net income/share CAGR above 1.5x AVGO's 187.85% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
26.69%
Below 50% of AVGO's 187.85%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
61.84%
Below 50% of AVGO's 6203.06%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
55.49%
Equity/share CAGR of 55.49% while AVGO is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
28.39%
Equity/share CAGR of 28.39% while AVGO is zero. Bruce Berkowitz might see a minor advantage that could compound if the firm maintains positive net worth growth.
34.19%
Below 50% of AVGO's 162.54%. Michael Burry suspects a serious short-term disadvantage in building book value.
707.91%
Dividend/share CAGR of 707.91% while AVGO is zero. Bruce Berkowitz sees a slight advantage in stepping up payouts steadily.
113.40%
Dividend/share CAGR of 113.40% while AVGO is zero. Bruce Berkowitz sees a minor advantage in stepping up distributions, even modestly.
56.13%
3Y dividend/share CAGR of 56.13% while AVGO is zero. Bruce Berkowitz sees a minor positive difference that could attract dividend-focused investors.
-0.37%
Firm’s AR is declining while AVGO shows 20.44%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
-1.96%
Both reduce inventory yoy. Martin Whitman suspects a broader move to lean operations or industry slowdown in demand.
5.09%
Asset growth 1.25-1.5x AVGO's 3.98%. Bruce Berkowitz sees if the firm's investments effectively outpace the competitor in future returns.
3.10%
50-75% of AVGO's 5.20%. Martin Whitman suspects weaker earnings or capital allocation vs. the competitor.
20.99%
We have some new debt while AVGO reduces theirs. John Neff sees the competitor as more cautious unless our expansions pay off strongly.
-3.54%
Our R&D shrinks while AVGO invests at 5.95%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-0.66%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.